Mechanism of Darunavir (DRV)’s High Genetic Barrier to HIV-1 Resistance: A Key V32I Substitution in Protease Rarely Occurs, but Once It Occurs, It Predisposes HIV-1 To Develop DRV Resistance

Manabu Aoki,a,b,c,d Debananda Das,a Hironori Hayashi,d Hiromi Aoki-Ogata,a,b,c Yuki Takamatsu,a Arun K. Ghosh,e,f Hiroaki Mitsuya,a,b,c,d

ABSTRACT Darunavir (DRV) has bimodal activity against HIV-1 protease, enzymatic inhibition and protease dimerization inhibition, and has an extremely high genetic barrier against development of drug resistance. We previously generated a highly DRV-resistant HIV-1 variant (HIV\textsubscript{DRV\textsuperscript{R}P51}). We also reported that four amino acid substitutions (V32I, L33F, I54M, and I84V) identified in the protease of HIV\textsubscript{DRV\textsuperscript{R}P51} are largely responsible for its high-level resistance to DRV. Here, we attempted to elucidate the role of each of the four amino acid substitutions in the development of DRV resistance. We found that V32I is a key substitution, which rarely occurs, but once it occurs, it predisposes HIV-1 to develop high-level DRV resistance. When two infectious recombinant HIV-1 clones carrying I54M and I84V (rHIV\textsubscript{I54M} and rHIV\textsubscript{I84V}, respectively) were selected in the presence of DRV, V32I emerged, and the virus rapidly developed high-level DRV resistance. rHIV\textsubscript{V32I} also developed high-level DRV resistance. However, wild-type HIV\textsubscript{NL-4-3} (rHIV\textsubscript{WT}) failed to acquire V32I and did not develop DRV resistance. Compared to rHIV\textsubscript{WT}, rHIV\textsubscript{V32I} was highly susceptible to DRV and had significantly reduced fitness, explaining why V32I did not emerge upon selection of rHIV\textsubscript{WT} with DRV. When the only substitution is at residue 32, structural analysis revealed much stronger van der Waals interactions between DRV and I-32 than between DRV and V-32. These results suggest that V32I is a critical amino acid substitution in multiple pathways toward HIV-1’s DRV resistance development and elucidate, at least in part, a mechanism of DRV’s high genetic barrier to development of drug resistance. The results also show that attention should be paid to the initiation or continuation of DRV-containing regimens in people with HIV-1 containing the V32I substitution.

IMPORTANCE Darunavir (DRV) is the only protease inhibitor (PI) recommended as a first-line therapeutic and represents the most widely used PI for treating HIV-1-infected individuals. DRV possesses a high genetic barrier to development of HIV-1’s drug resistance. However, the mechanism(s) of the DRV’s high genetic barrier remains unclear. Here, we show that the preexistence of certain single amino acid substitutions such as V32I, I54M, A71V, and I84V in HIV-1 protease facilitates the development of high-level DRV resistance. Interestingly, all in vitro-selected highly DRV-resistant HIV-1 variants have V32I as a key substitution, explaining their high level of resistance to DRV.
resistant HIV-1 variants acquired V32I but never emerged in wild-type HIV (HIVWT), and V32I itself rendered HIV-1 more sensitive to DRV and reduced viral fitness compared to HIVWT, strongly suggesting that the emergence of V32I plays a critical role in the development of HIV-1’s resistance to DRV. Our results would be of benefit in the treatment of HIV-1-infected patients receiving DRV-containing regimens.

**KEYWORDS** darunavir, genetic barrier, drug resistance, dual mechanism, HIV-1, V32I, protease inhibitors

Combination antiretroviral therapy (cART) for HIV-1 infection and AIDS available at this time potently suppresses the replication of HIV-1 and significantly extends the life expectancy of HIV-1-infected individuals (1, 2). However, our ability to provide effective long-term cART remains a complex issue, since many of those individuals who initially achieve favorable viral suppression to undetected levels eventually suffer treatment failure. Nevertheless, in regard to the propensity of HIV-1 to develop resistance to antiretroviral agents, protease inhibitors (PIs) generally have high genetic barrier against resistance. In particular, the latest FDA-approved PI, darunavir (DRV), the only PI recommended for first-line therapy (3), has a favorable genetic barrier apparently because of its dual mechanism of action, (i) protease enzymatic inhibition activity and (ii) protease dimerization inhibition activity (4–6), and it currently represents the most widely used PI for treating HIV-1-infected individuals. Indeed, it has been shown that multiple attempts to select HIV-1 variants resistant to DRV have failed when such selection attempts were made using a single wild-type HIV-1 strain as a starting virus population (7–12), although DRV resistance has been observed clinically (13, 14). In this regard, we previously generated highly DRV-resistant HIV-1 variants in vitro (HIV-1DRVR10, HIV-1DRVR30, and HIV-1DRVR51) by employing a mixture of eight multidrug-resistant HIV-1 variants as a starting HIV-1 population (8). The most DRV-resistant isolate, HIV-1DRV51, had acquired four major amino acid substitutions in its protease (V32I, L33F, I54M, and I84V), which have been shown to be responsible for the DRV resistance of HIV-1DRV51 (5, 6). Moreover, the emergence of DRV-resistant HIV-1 variants has also been reported in patients receiving long-term DRV-containing cART (13), and those with such DRV-resistant HIV-1 variants have experienced treatment failure (14).

In the present study, we attempted to elucidate the mechanism by which HIV-1 eventually acquires resistance to DRV. We demonstrate that one of the four critical amino acid substitutions, V32I, serves as a key substitution, which rarely occurs in in vitro selection attempts, but once it occurs, it predisposes HIV-1 to develop high-level DRV resistance. The present data not only explain the mechanisms of DRV’s high genetic barrier well but also suggest that the initiation or continuation of DRV-containing regimens in individuals harboring HIV-1 variants with a V32I substitution must be carefully considered and monitored.

**RESULTS**

**Failure of selection of DRV-resistant HIV-1 variants as wild-type HIV-1 strains were used as starting virus populations.** Our group and others have previously reported that the selection of wild-type HIV-1 strains in the presence of each of eight FDA-approved protease inhibitors (PIs) (ritonavir, indinavir, nelfinavir, saquinavir, amprenavir [APV], lopinavir, tipranavir, and atazanavir) readily gave HIV-1 variants resistant to each PI over 20 to 67 weeks (7–10, 15, 16). However, when HIV-1 was selected against DRV using standardized selection protocols, the development of HIV-1 variants resistant to DRV was not seen or much delayed, and no significant DRV resistance-associated amino acid substitutions were identified (7–12). Figure 1A shows that during selection of an infectious HIV-1NL4-3 clone (rHIVWT) in the presence of DRV, rHIVWT failed to replicate in the presence of >0.075 μM DRV even after 50 weeks of selection, in line with our previous findings (8–11).
As previously reported, the highly DRV-resistant HIV-1 variant, HIV-DRV^R_P51, contains four major DRV resistance-associated amino acid substitutions (V32I, L33F, I54M, and I84V) in its protease (8), which are responsible for the loss of DRV’s protease dimerization inhibition activity (5). However, the role of each of the four substitutions in the development of HIV-1’s DRV resistance has remained to be determined. Thus, we newly generated a panel of recombinant infectious HIV-1 clones using the site-directed mutagenesis method. When three such recombinant clones (rHIVV32I/L33F/I54M/I84V, rHIVV32I/I54M, and rHIVL33F/I84V) were propagated in increasing concentrations of DRV, rHIVV32I/L33F/I54M/I84V readily acquired high-level DRV resistance and replicated in the presence of 5µM DRV by 17 weeks of selection (Fig. 1A), followed by rHIVV32I/I54M and rHIVL33F/I84V, which vigorously replicated in the presence of 1µM DRV by the end of 22 and 26 weeks of selection, respectively (Fig. 1A). rHIVV32I, rHIVI54M, and rHIVI84V acquired DRV resistance somewhat slower than the double and quadruple mutants tested above, but they did replicate in the presence of ≥1µM DRV by the end of 36 weeks of selection (Fig. 1B), while rHIVL33F failed to acquire DRV resistance by the end of week 50 of selection (Fig. 1B).

**The V32I substitution predisposes HIV-1 to acquisition of DRV resistance.** In order to clarify which amino acid substitutions emerged in each of the HIV-1 clones, the amino acid sequence of the protease-encoding region of each variant was directly determined using proviral DNA isolated from the HIV-1-producing MT-4 cells at various time points of selection. HIV^WT_50 had acquired three substitutions, M46L, K55N, and V82I, by 50 weeks. HIVL33F_50, which apparently did not acquire DRV resistance (Fig. 1B), had acquired only K43T, whose significance in the development of PI resistance is well-known (17) (Fig. 2A). It was noteworthy that all six clones that eventually developed DRV resistance (HIVV32I/L33F/I54M/I84V-WK17, HIVV32I/I54M-WK22, HIVL33F/I84V-WK26, HIVI84V-WK29, HIVV32I/WK36, and HIVI54M-WK36) (Fig. 1) contained the V32I substitution, although other substitutions such as L10F, L33F, M46I, A71V, and I84V had been acquired in a subset of the six clones (Fig. 2A), suggesting that V32I substitution might have played an important role in the pathway of DRV resistance development. We, therefore, further asked whether the two clones that did not develop DRV resistance by the end of 50 weeks of selection (HIV^WT_50 and HIVI33F_50)
had not acquired V32I (Fig. 2A). As shown in Fig. 2B, V32I was not seen in any of the 20 clones examined for HIVWT-WK50 and HIVL33F-WK50, suggesting that the emergence of V32I might have been associated with the eventual development of DRV resistance in the 6 clones described above. It was also noted that in five of the six clones, A71V had emerged in quite early stages of DRV selection (by the end of 5 to 8 weeks of selection), followed by the emergence of V32I substitution. It is also noted that in five of the six clones examined are shown to the right of the sequences.

### FIG 2

Emergence of the V32I substitution during the selection of highly DRV-resistant HIV-1 variants but not in HIVWT and HIVL33F. (A) Amino acid sequences deduced from the nucleotide sequence of the protease-encoding region (direct sequencing) were determined using proviral DNA. In the selection with DRV, proviral DNA was extracted at week 50 for HIVWT and HIVL33F, at week 36 for HIVV32I, at weeks 7, 24, and 36 for HIVI54M, at weeks 8, 17 and 29 for HIVI84V, at week 22 for HIVV32I/I54M, at week 26 for HIVV32I/I54M, and at week 17 for HIVV32I/I54M/I84V. (B) Absence of the V32I substitution in two infectious clones, HIVWT and HIVL33F, which were selected with DRV over 50 weeks. Two clones, rHIVWT and rHIVL33F, selected with DRV over 50 weeks (generating HIVWT-WK50 and HIVL33F-WK50, respectively), apparently failed to develop DRV resistance as shown in Fig. 1. To confirm the absence of V32I, HIVWT-WK50 and HIVL33F-WK50 were further cloned (20 clones), and each clone generated was sequenced. Note that the V32I substitution did not emerge in either of the virus populations. The consensus sequence of pNL4-3 is illustrated at the top of panels A and B as a reference. Amino acids that are identical to those in the consensus sequence at individual amino acid positions are indicated by dots. Fractions of the virus which each clone is presumed to have originated from over the total number of clones examined are shown to the right of the sequences.

**V32I renders rHIVWT highly susceptible to DRV.** We next attempted to determine how each of the four amino acid substitutions contributed to the high-level DRV resistance of HIVDRV\\_PS1. To this end, we first replaced the Gag- and protease-encoding genes of HIVNL4-3 with genes derived from HIVDRV\\_PS1 and obtained a recombinant infectious HIV-1 clone, designated rHIVDRV\\_PS1. This rHIVDRV\\_PS1 clone was confirmed to be highly resistant to DRV, showing a 50% inhibitory concentration (IC50) of 330 nM, 106-fold greater than that of rHIVWT (Table 1). We then reverted each of the four substitutions to the wild-type amino acid in rHIVDRV\\_PS1 via site-directed mutagenesis. A newly generated infectious clone, rHIVDRV\\_PS1\\_I32V, in which the substitution V32I was
V32I is Key in HIV-1’s DRV Resistance Development

TABLE 1 Antiviral activity of DRV against HIV-1 clones carrying various mutations in protease

| Infectious clone       | Amino acid substitution(s) in PR | IC₅₀ (mean ± SD) (nM) (fold change)ᵃ |
|------------------------|----------------------------------|--------------------------------------|
| rHIVWT                 | None                             | 3.1 ± 0.3 (2.8) 24 ± 2 30 ± 9 4.9 ± 3.2 |
| rHIVDRV⁸₉₃₉V            | L10I, I15V, K20R, L24I, L33F, M36I, M46L, I54M, L63P, K70Q, V82I, I84V, L89M | 29 ± 8 (9) ND ND ND |
| rHIVDRV⁸₃₃₃F            | L10I, I15V, K20R, L24I, V32I, M36I, M46L, I54M, L63P, K70Q, V82I, I84V, L89M | 120 ± 33 (38) ND ND ND |
| rHIVDRV⁸₅₄₄M            | L10I, I15V, K20R, L24I, V32I, L33F, M36I, M46L, L63P, K70Q, V82I, I84V, L89M | 43 ± 15 (14) ND ND ND |
| rHIVDRV⁸₄₈₄V            | L10I, I15V, K20R, L24I, V32I, L33F, M36I, M46L, I54M, L63P, K70Q, V82I, I84V, L89M | 28 ± 6 (9) ND ND ND |
| rHIVDRV⁸₁₅₃F            | L10I, I15V, K20R, L24I, V32I, L33F, M36I, M46L, I54M, L63P, K70Q, V82I, I84V, L89M | 330 ± 10 (106) ND ND ND |
| rHIVV₃₂I/V₃₃F/I₅₄M/I₈₄V| V32I, L33F, I54M, I84V            | 639 ± 17 (205) ND ND ND |
| rHIVV₃₂I               | V32I                             | 0.2 ± 0.05 (0.06) 31 ± 3 (1.3) 32 ± 6 (1.1) 4.7 ± 0.5 (1.0) |
| rHIVV₃₃F               | L33F                             | 3.2 ± 0.1 (1.0) 35 ± 2 (1.3) 45 ± 12 (1.5) 5.6 ± 1.1 (1.1) |
| rHIVV₅₄₄M              | I54M                             | 2.7 ± 0.1 (0.9) 324 ± 86 (13) 34 ± 17 (1.1) 5.1 ± 2.2 (1.0) |
| rHIVV₈₄₄V              | I84V                             | 3.3 ± 0.3 (1.1) 313 ± 98 (13) 44 ± 18 (1.5) 6.4 ± 6.0 (1.3) |

ᵃData shown represent mean IC₅₀ values (±1 standard deviation) derived from the results of three independent experiments conducted in triplicate. The IC₅₀s were determined by employing MT-4 cells exposed to each infectious HIV-1 clone (50 TCID₅₀s) in the presence of each inhibitor and using the inhibition of p24 Gag protein production as an end point. The fold change values in parentheses were calculated by dividing IC₅₀ against each virus by the IC₅₀ against rHIVWT. ND, not determined.

ᵇAPV, amprenavir, a protease inhibitor.
ᶜAZT, zidovudine, a nucleoside reverse transcriptase inhibitor.
ᵈRAL, raltegravir, an integrase strand transfer inhibitor.

reverted back to Val, was found to be only moderately resistant to DRV with an IC₅₀ of 29 nM. The IC₅₀ of rHIVDRV⁸₃₃₃F, rHIVDRV⁸₅₄₄M, and rHIVDRV⁸₄₈₄V turned out to be 120, 43, and 28 nM, respectively (Table 1). These data strongly suggested that the order of the magnitude of contribution to the high-level DRV resistance was V32I ~ L84V > I54M > > L33F. We subsequently introduced all four substitutions or each single substitution into HIVNL4-3 (rHIVWT), generating rHIVV₃₂I/L33F/I₅₄M/I₈₄V, rHIVV₃₂I, rHIVL₃₃F, rHIVV₅₄₄M, and rHIVV₈₄₄V. As expected, rHIVV₃₂I/L₃₃F/I₅₄M/I₈₄V proved to be highly resistant to DRV with an IC₅₀ of 639 nM, while rHIVV₃₃F, rHIVV₅₄₄M, and rHIVV₈₄₄V were as sensitive as rHIVWT with IC₅₀s of ~3 nM, virtually identical to that of rHIVWT, in line with our previous report (5). It is noteworthy that rHIVV₃₂I was hypersensitive to DRV with an IC₅₀ of 0.2 nM, 16.7-fold more sensitive to DRV compared to rHIVWT (Table 1), suggesting that since the emergence of DRV-hypersensitive HIVV₃₂I would be prohibitive in the presence of DRV, rHIVWT is not likely to directly acquire V32I substitution.

Since the presence of A71V might predispose HIV-1 to its acquisition of V32I as discussed above, we generated various recombinant infectious HIV-1 clones and determined their susceptibility to DRV (Table 2). The addition of A71V to rHIVV₃₂I that was

TABLE 2 Antiviral activity of DRV against HIV-1 clones carrying V32I, I54M, A71V, and/or I84V

| Infectious clone       | Amino acid substitution(s) in PR | IC₅₀ (mean ± SD) (nM) (fold change)ᵃ |
|------------------------|----------------------------------|--------------------------------------|
| rHIVWT                 | None                             | 3.1 ± 0.3ᵃ |
| rHIVV₃₂I               | V32I                             | 0.2 ± 0.05 (0.06)ᵇ |
| rHIVA₇₁V               | A71V                             | 3.3 ± 0.2 (1.1) |
| rHIVV₃₂I/A₇₁V          | V32I, A71V                       | 2.8 ± 0.2 (0.9) |
| rHIVV₃₂I/I₅₄M          | V32I, I54M                       | 1.7 ± 0.4 (0.5) |
| rHIVV₃₂I/I₈₄V          | V32I, I84V                       | 0.42 ± 0.13 (0.13) |
| rHIVV₃₂I/I₅₄M/A₇₁V     | V32I, I54M, A71V                 | 27 ± 5 (8.6) |
| rHIVV₃₂I/A₇₁V/I₈₄V     | V32I, A71V, I84V                 | 35 ± 2 (11) |

ᵃData shown represent mean IC₅₀ values (±1 standard deviation) derived from the results of three independent experiments conducted in triplicate. The IC₅₀s were determined employing MT-4 cells exposed to each infectious HIV-1 clone (50 TCID₅₀s) in the presence of DRV and using the inhibition of p24 Gag protein production as an end point. The fold change values in parentheses were calculated by dividing IC₅₀ against each virus by the IC₅₀ against rHIVWT. ND, not determined.
ᵇThese values are from Table 1 and serve as reference values.
hypersensitive to DRV (IC$_{50}$ = 0.2 nM), generating rHIVV32I/A71V, abrogated the DRV hypersensitivity of rHIVV32I to DRV and the IC$_{50}$ of rHIVV32I/A71V became virtually the same as that of rHIVWT (2.8 versus 3.1 nM). Two clones, rHIVV32I/I54M and rHIVV32I/I84V, were also found hypersensitive to DRV with IC$_{50}$s of 1.7 and 0.42 nM, suggesting that these two clones would not emerge in the presence of DRV. However, the addition of A71V to these two clones, generating rHIVV32I/I54M/A71V and rHIVV32I/A71V/I84V, acquired significant resistance to DRV with their IC$_{50}$s of 27 and 35 nM, respectively (Table 2). These data strongly suggest that while the A71V substitution by itself confers no particular DRV resistance on HIV-1, combining it with the V32I substitution appears to suppress the hypersusceptibility phenotype conferred by V32I substitution and retains the wild-type level of susceptibility of rHIVA71V—as if the effect of V32I substitution were suppressed. Furthermore, when the A71V substitution is combined with V32I and I54M or V32I and I84V (both of which by themselves appear to be hypersensitive on their own), the resultant HIV-1 yields high-level DRV resistance (Table 2).

**A71V predisposes HIV-1 to its acquisition of high-level DRV resistance.** We further attempted to examine whether the addition of A71V to rHIVWT, generating rHIVV32I/A71V, renders rHIVWT inclined to eventually develop high-level DRV resistance. Figure 3 shows that the selection of rHIVV32I/A71V with DRV led to the emergence of high-level DRV resistance. Since the M46I substitution is often seen in various PI-resistant HIV-1 variants (18) and that substitution was also seen in the present study (Fig. 2A), we also generated rHIVM46I and selected it in the presence of DRV. However, DRV selection of rHIVM46I did not result in the emergence of high-level DRV-resistant variants (Fig. 3). These data strongly suggest that the presence of A71V predisposes HIV-1 to its acquisition of V32I in the pathway toward HIV-1’s acquisition of high-level DRV resistance at least when rHIVWT (HIV-1NL4-3) was employed as a starting viral population in the selection with DRV.

**V32I increases DRV’s protease dimerization inhibition and reduces viral fitness.** Since the potent activity of DRV against HIV-1 is associated with the bimodal anti-HIV-1 activity (4–6), (i) protease’s enzymatic activity inhibition and (ii) protease dimerization inhibition, our observation as described above that rHIVV32I was hypersensitive to DRV prompted us to examine the susceptibility of rHIVV32I to DRV’s protease dimerization inhibition activity. As assessed by the fluorescence resonance energy transfer (FRET)-based HIV-1 expression assay (Fig. 4A), the mean CFPA/B ratios (ratio of intensities of cyan fluorescent protein [CFP] fluorescence after photobleaching to those of CFP fluorescence before photobleaching) determined for rHIVWT in the absence of DRV and in the presence of 10 nM DRV were 1.07 and 1.04, respectively, indicating that protease
Dimerization occurred (Fig. 4B). In the presence of 100 nM DRV, the ratio was 0.89, indicating that 100 nM DRV blocked dimerization. However, when rHIVV32I was used in the assay, as little as 1 nM DRV blocked protease dimerization, giving a CFPA/B ratio of 0.83 (Fig. 4B). These data indicate that rHIVV32I was much more sensitive to DRV’s dimerization inhibition (by a factor of 100) than rHIVWT.

V32I compromises the replication fitness of rHIVWT, but the addition of A71V mitigates the compromised fitness. We further attempted to examine the replication kinetics of three infectious clones, rHIVWT, rHIVV32I, and rHIVV32I/A71V in the presence or absence of DRV. The replication kinetic profiles of these three clones were apparently comparable in the absence of DRV (Fig. 5A), although the replication of rHIVV32I was, as expected, totally suppressed in the presence of 3 nM DRV (Fig. 5B). We therefore determined detailed replication fitness of rHIVWT and rHIVV32I employing the compet-
positive HIV-1 replication assay (CHRA) as previously described (19). It was clearly shown that rHIVV32I had compromised replication fitness compared to rHIVWT both in the presence and absence of 3 nM DRV (Fig. 5C). Interestingly, the addition of A71V substitution to rHIVV32I clearly mitigated the compromised replication fitness of rHIVV32I (Fig. 5D). These data suggest that the presence of A71V enables and probably accelerates the emergence of V32I.

The V32I substitution increases van der Waals interactions with DRV. We analyzed the structural interactions of DRV with Val32 by analyzing the crystal structure of DRV-HIV-1 protease (PDB identifier [ID] or accession no. 4HLA) (20). Connolly surfaces for DRV, Val32 and Val32 = Val32 = , were generated and the interactions among the surfaces were analyzed. As shown in the top left portions of Fig. 6A and B, Val32 has good interactions with the bis-tetrahydrofuranylurethane (bis-THF), while Val32 = interacts with the aminobenzene moieties of DRV. We then analyzed the interactions of V32I mutant protease (PRV32I) with DRV. As shown in the bottom left panel of Fig. 6B, bis-THF has enhanced interactions with substituted Ile32 than with Val32 of wild-type protease (PRWT). The substituted Ile32 = also has enhanced interactions with the aminobenzene group of DRV than does Val32 in PRWT. Overall, the Connolly surface interactions suggested better interactions of DRV with both Ile32 and Ile32 = of V32I-substituted
protease (PR\textsubscript{V32I}) than with Val32 and Val32' of PRWT. We further analyzed the interactions of amprenavir (APV) with PRWT in comparison with PRV32I. APV has a THF group as the P2 ligand (Fig. 6A), and it does interact with Val32 (top right panel of Fig. 6B). However, there are no changes in the interactions of the THF group with Ile32 (bottom right panel of Fig. 6B). In contrast, as described above, the P2 \textit{bis}-THF of DRV has much better interactions with Ile32 than it does with Val32. The changes in the interactions of APV on the P2' site with Ile32' over Val32 are similar to the corresponding changes in the interactions of DRV. In conclusion, the presence of the \textit{bis}-THF group in DRV (compared to THF in APV) is responsible for the increased van der Waals interactions with Ile32 of PRV32I. This increase in van der Waals interactions must be partly responsible for the increased susceptibility of rHIV\textsubscript{V32I} to DRV.

**DISCUSSION**

DRV, the latest FDA-approved PI, is the only PI recommended for first-line therapy (3) and has a favorable genetic barrier against emergence of resistant variants. The latter might be because of its dual mechanism of action: (i) protease enzymatic inhibition activity and (ii) protease dimerization inhibition activity (4–6). DRV currently represents the most widely used PI for treating HIV-1-infected individuals. The relatively rare emergence of HIV-1 variants resistant to DRV in the setting of clinical applications was noted, which was explained with the findings in the early phase of clinical development of DRV that multiple attempts to select DRV-resistant HIV-1 variants failed when such selection attempts were conducted using a single wild-type HIV-1 strain as a starting virus population (7–12). However, when a mixture of eight multidrug-
resistant HIV-1 variants was employed as a starting HIV-1 population (8), highly DRV-resistant HIV-1 variants (HIV-1DRV\(_{P10}\), HIV-1DRV\(_{P30}\), and HIV-1DRV\(_{P51}\)) emerged relatively quickly (8). In fact, the emergence of DRV-resistant HIV-1 variants has been reported in patients receiving long-term DRV-containing cART (13).

In the present study, we attempted to elucidate the mechanisms by which DRV rarely allows HIV-1 to develop DRV-resistant HIV-1 variants so that novel PIs that more profoundly resist against the emergence of resistant variants can be designed. Here, we demonstrate that one of the four critical amino acid substitutions responsible for DRV resistance, V32I, serves as a key substitution; it rarely occurs in in vitro selection attempts, but once it occurs, it predisposes HIV-1 to develop high-level DRV resistance. As shown in Fig. 7A, when we selected three infectious clones (HIV\(_{WT}\), HIV\(_{L33F}\), and HIV\(_{M46I}\)) with DRV, none of those clones developed DRV resistance. However, when two clones (HIV\(_{V32I}\) and HIV\(_{I54M}\)) were selected, HIV\(_{V32I}\) and HIV\(_{I54M}\) relatively rapidly acquired A71V, and HIV\(_{I54M}\) subsequently acquired V32I. These virus isolates continued to acquire multiple amino acid substitutions and became highly resistant to DRV. Upon DRV selection, HIV\(_{V32I/54M}\) quickly acquired A71V and became highly resistant to DRV. HIV\(_{V32I/54M}\) quickly acquired A71V, subsequently acquired V32I, and became resistant to DRV. HIV\(_{V32I/54M}\) continued to propagate in the presence of DRV, acquired V32I but without acquiring A71V, and became resistant to DRV. HIV\(_{V32I/31/54M}\)'s acquisition of high-level DRV resistance despite the absence of A71V strongly suggest that its DRV resistance acquisition involved alternate albeit unidentified pathway of DRV resistance development. (B) The locations of V32, L33F, M46, I54, A71, and I84 are shown in the dimerized protease. V32, I54, and I84 are located in the active site of the dimerized protease; however, A71 is distant from the active site.

![FIG 7](mbio.asm.org) The mature dimerized HIV-1 protease in complex with DRV and proposed pathway of development of DRV resistance. (A) Proposed pathway of development of DRV resistance of HIV-1. Upon DRV selection, rHIV\(_{WT}\), rHIV\(_{L33F}\), and rHIV\(_{M46I}\) clones did not develop DRV resistance. rHIV\(_{V32I}\) and rHIV\(_{I54M}\) relatively rapidly acquired A71V, and rHIV\(_{V32I/54M}\) subsequently acquired V32I. These clones continued to acquire multiple amino acid substitutions and became highly resistant to DRV. Upon DRV selection, rHIV\(_{V32I/54M}\) quickly acquired A71V and became highly resistant to DRV. rHIV\(_{V32I/54M}\) acquired V32I and eventually became resistant to DRV. rHIV\(_{V32I/54M}\) quickly acquired A71V, subsequently acquired V32I, and became resistant to DRV. rHIV\(_{I54M}\) continued to propagate in the presence of DRV, acquired V32I but without acquiring A71V, and became resistant to DRV. rHIV\(_{V32I/31/54M}\)'s acquisition of high-level DRV resistance despite the absence of A71V strongly suggest that its DRV resistance acquisition involved alternate albeit unidentified pathway of DRV resistance development. (B) The locations of V32, L33F, M46, I54, A71, and I84 are shown in the dimerized protease. V32, I54, and I84 are located in the active site of the dimerized protease; however, A71 is distant from the active site.
compared to 3.5 to 5.4% of HIV-1 isolates from PI-naive patients (22, 23). In one study by Sterrantino et al. (24), involving 1,104 patients receiving DRV-containing regimens, 118 patients (10.7%) experienced treatment failure. This study (24) showed that V32I and I84V substitutions in protease played a significant role, but there was no mention of A71V. In contrast, a set of data compiled for NDA21-976/S003 and NDA21-976/S004 clearly indicates that 10 amino acid substitutions including L10F, V32I, L33F, S37N, M46I, I47V, I50V, L63P, A71V, and I84V are the most prevalent (https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021976s003s004lbl.pdf). Nevertheless, no detailed analysis on the role of A71V in the development of DRV resistance has been reported.

When rHIVV32I/I54M was selected, this clone acquired A71V more quickly by 5 weeks of selection and became capable of replicating in the presence of 1 μM DRV by 22 weeks of selection (Fig. 1A). When rHIVA71V was selected, this clone acquired V32I and other amino acid substitutions and became capable of propagating in the presence of 1 μM DRV by 25 weeks of selection (Fig. 3). When rHIVl84V was selected, this clone quickly acquired A71V by 8 weeks of selection, subsequently acquired V32I by 17 weeks of selection, and was replicating in the presence of 1 μM DRV by 29 weeks of selection (Fig. 1B and Fig. 2A). It is interesting that when rHIV33F/84V was selected, this clone continued to propagate in the presence of increasing concentrations of DRV, acquired V32I (as examined at week 26) but without acquiring A71V, and became capable of propagating in the presence of 1 μM DRV by 26 weeks of selection. rHIV33F/84V's acquisition of high-level DRV resistance despite the absence of A71V strongly suggested that its DRV resistance acquisition involved an alternate albeit unidentified pathway of DRV resistance development. The reason why the three clones (rHIVWT, rHIV33F, and rHIVM46I) failed to develop DRV resistance is unknown at this time, although it is possible that the acquisition of A71V, a secondary substitution observed among HIV-1 isolates resistant to various PIs (25, 26), might render each clone more susceptible to DRV and/or compromise their replication fitness, and A71V substitution rarely emerged. It is noteworthy that the IC50S of rHIVWT and rHIVA71V were virtually the same (3.1 and 3.3 μM, respectively), although the cell-based assay for determining IC50S employed is as short as 7 days and it is of limited significance in strictly comparing the susceptibility or replication fitness of HIV-1.

It should be noted that all the highly DRV-resistant HIV-1 variants (HIV-1DRV_R10, HIV-1DRV_R30, and HIV-1DRV_R51) did not contain the A71V substitution as the PR-encoding gene of those variants were directly sequenced, although when a highly drug-resistant clinical HIV-1 isolate, HIVc, was selected with DRV, that isolate eventually acquired A71V by passage 50 (8). As discussed above, in regard to the selection results of rHIV33F/84V, which developed high-level DRV resistance without acquiring A71V, the development of high-level DRV resistance in cases of HIV-1DRV_R10, HIV-1DRV_R30, and HIV-1DRV_R51 also involved alternative albeit unidentified pathways in the development of DRV resistance.

In the present study, we concluded that the V32I substitution serves as a key substitution, which rarely occurs in the presence of DRV without other DRV resistance-predisposing amino acid substitutions, but once it occurs, it significantly predisposes HIV-1 to develop high-level DRV resistance. As summarized in the proposed pathway of development of DRV resistance (Fig. 7B), all three resultant highly DRV-resistant variants (HIV-1DRV_R10, HIV-1DRV_R30, and HIV-1DRV_R51) contained the V32I substitution (8), and all the HIV-1 infectious clones that were selected with DRV and developed high-level DRV resistance also contained the substitution. In fact, the presence of the V32I substitution has been significantly associated with treatment failure in those receiving DRV-containing regimens. The study by Lambert-Niclot et al. (27) reported that the V32I substitution was seen in 24% of clinical HIV-1 isolates from 54 multiple-PI-experienced but non-DRV-exposed HIV-1-infected individuals, but the prevalence of the substitution increased to 57% in those who subsequently received DRV-containing regimens and underwent treatment failure with such regimens. The study by Delaugerre et al. showed that the V32I substitution was present in 64% of HIV-1 isolates from 25 DRV-naive patients after treatment failure (28). Sterrantino et al. also reported that
among 1,104 patients receiving DRV-containing regimens, the substitution was seen in 20.3% of HIV-1 isolates from 118 patients undergoing treatment failure but in only 7.5% of 986 patients responding to the regimens (24). It is noteworthy that V32I was reportedly involved in the development of pan-PI resistance including DRV resistance as estimated by an independent correlation network analysis of amino acid substitutions identified in HIV-1 proteases studied from more than 10,000 patients receiving PI-containing regimens (29). These data suggest that the V32I substitution is strongly associated with the development of DRV resistance.

It is noteworthy that the key amino acid substitutions focused on in the present study, including not only V32I but also L33F, I54M, and I84V, as a single substitution do not by themselves confer resistance to DRV. Importantly, the V32I substitution did confer hypersusceptibility to DRV, while the other three substitutions did not significantly change the susceptibility (Table 1). These substitutions are part of rHIVDRV$^{R_{PSI}}$, which is highly resistant to DRV (106-fold-greater IC$_{50}$ compared to DRV’s IC$_{50}$ against rHIV$^{WT}$). However, when we introduced the reversion of each of those substitutions into the highly DRV-resistant rHIV$^{DRV R_{PSI}}$, three partially reverted clones (rHIV$^{DRV R_{PSI} V32I}$, rHIV$^{DRV R_{PSI} M54I}$, and rHIV$^{DRV R_{PSI} V84I}$) became significantly less resistant to DRV (9- to 14-fold) and rHIV$^{DRV R_{PSI} F33L}$ also became less resistant to DRV (38-fold) (Table 1). These data strongly suggest that these four substitutions are unusual in that they somehow affect the ability of other mutations in the background to confer high-level DRV resistance. In particular, considering that the V32I substitution is seen in some HIV-1 variants resistant to other PIs than DRV (21, 30), the V32I substitution is not necessarily specific to DRV resistance but likely associated with pan-PI resistance as well.

It is also noteworthy that substitutions other than the four key substitutions present in rHIV$^{DRV R_{PSI}}$ might be DRV specific; however, considering that rHIV$^{DRV R_{PSI}}$ is highly resistant to all the existing FDA-approved PIs examined as shown in previous reports (8, 10), it is also possible that substitutions other than the key substitutions are responsible for the acquisition of HIV-1 of pan-PI resistance. The exact mechanism as to how other substitutions play a role(s) in conferring DRV-specific resistance or pan-PI resistance remains to be determined. Structurally, it is plausible to presume that the four key substitutions change the structure of PR in some global way that is important for optimal PR functions while conferring DRV resistance. In any event, the data together strongly suggest that the V32I substitution (and the three associated substitutions as a single substitution) is not by itself a DRV resistance-associated mutation, but does facilitate DRV resistance when present.

Structurally, A71 is located distant from the enzymatic active site and the hydrophobic cavity of PR (Fig. 7B). Skálová et al. (31) reported that mutations can result in the movement of $\beta$-sheets, which causes structural changes far away from the location of the mutation. They propose that there are hydrogen bonds involving multiple $\beta$-sheets between residues 71 and 64, residues 65 and 14, and residues 13 and 20. The side chain of A71 is oriented toward the hydrophobic cavity of PR, and changing alanine to valine requires more space to hold valine’s bulkier side chain. The A71V substitution likely changes the configuration of the A71-containing $\beta$-sheet and the hydrogen bond network propagating to the binding pocket, changing the shape of the “ligand binding tunnel,” and affecting the interactions, in which the catalytic site amino acid residues (Asp25 and Asp25’) are involved (31). These structural insights can help explain why the IC$_{50}$ of rHIV$^{V32I/A71V}$ is comparable to that of rHIV$^{WT}$ (Table 2), while rHIV$^{V32I/I54M}$ and rHIV$^{V32I/I84V}$ were still highly sensitive to DRV (Table 2). Furthermore, A71V compensated for the compromised viral fitness by acquisition of V32I (Fig. 5).

DRV has good van der Waals interactions with several protease residues. The bis-THF moiety of DRV has van der Waals interactions with Val32, and our structural modeling indicated that the interactions are substantially strengthened with substitution to Ile32 (Fig. 6B). In contrast, the THF moiety of APV, being significantly smaller, has similar interactions with both Val32 as well as Ile32 (Fig. 6B). These data partly explain why rHIV$^{V32I}$ is more sensitive to DRV, whereas the antiviral activity of APV does not change (Table 1). It is also noteworthy that HIV-1 carrying a single primary resistance-associated
Amino acid substitution may increase PI susceptibility when it occurs alone but increase PI resistance when it occurs in combination with other mutations (32).

The detailed structural analysis of the major amino acid substitutions conferring high-level DRV resistance on HIV-1 including V32I, L33F, IS4M, and I84V remains to be conducted. In this regard, we have expressed and purified several mutated proteases associated with DRV resistance such as that from highly DRV-resistant HIV-1 DRV R581 (5) that contains various amino acid substitutions including V32I, L33F, IS4M, and I84V, generated crystals of such proteases complexed with DRV and other PIs, and are analyzing the crystallographic structures of those complexes, which should give more in-depth insights in the understanding of the mechanism of the high genetic barrier of DRV. This molecular insight should be of help for the development of future PIs.

Amino acid codon substitutions in the HIV-1 genome that confer drug resistance are one of the major reasons for treatment failure. Hence, treatment guidelines recommend using genotyping tests prior to initiation of cART (3, 33). de Meyer et al. reported that 11 amino acid substitutions, V11I, V32I, L33F, I47V, IS0V, IS4L/M, G73S, L76V, I84V, and L89V, which appear to be associated with HIV-1 resistance against DRV, were identified among HIV-1 variants isolated from patients treated with DRV-including regimens on POWER studies. Some of these amino acid substitutions are reportedly associated with diminished virological response to DRV-containing regimens (34). However, to the best of our knowledge, no detailed studies on each of the amino acid substitutions have been reported. In the present study, at least four amino acid substitutions, V32I, IS4M, A71V, and I84V, obviously facilitate a high level of DRV resistance (Fig. 1B and Fig. 3), even though HIV-1 clones carrying each of the mutations showed sensitivity to DRV (Tables 1 and 2). These four mutations are commonly seen as PI-associated amino acid substitutions (21), and V32I (3.9%), IS4M (1.3%), and I84V (14.5%) were actually found in 1,021 genotypes from patients who failed in regimens including PIs other than DRV (30). In addition, A71V is also known as one of the common polymorphisms found in several percent PI-naïve patients (22, 23). Therefore, it is necessary to be careful when patients infected with HIV-1 carrying the four mutations are treated with DRV-containing regimens. The present data not only explain well the mechanisms of DRV’s high genetic barrier but also suggest that the initiation or continuation of DRV-containing regimens in individuals harboring HIV-1 variants with V32I substitution must be carefully considered and monitored.

MATERIALS AND METHODS

Cells and antiviral agents. MT-4 cells were grown in RPMI 1640-based culture medium, while COS-7 cells were propagated in Dulbecco’s modified Eagle’s medium. These media were supplemented with 10% fetal calf serum (FCS) (PAA Laboratories GmbH, Linz, Austria) plus 50 U of penicillin and 50 μg of kanamycin per ml. Darunavir (DRV) was synthesized as previously described (35). Amprenavir (APV), zidovudine (AZT), and raltegravir (RAL) were purchased from Sigma-Aldrich (St. Louis, MO).

Drug susceptibility assay. The susceptibility of infectious molecular HIV-1 clones to various antiviral agents was determined as previously described (36). Briefly, MT-4 cells (10⁵/ml) were exposed to 50 50% tissue culture infectious doses (TCID₅₀) of each infectious molecular HIV-1 clone in the presence or absence of various concentrations of each antiviral agent and were incubated at 37°C. On day 7 of culture each week, the supernatants were harvested, and the amounts of p24 Gag protein were determined by using a fully automated chemiluminescent-enzyme immunoassay system (Lumipulse G1200; Fujirebio Inc., Tokyo, Japan). The drug concentrations that suppressed the production of p24 Gag protein by 50% (50% inhibitory concentrations [IC₅₀]) were determined by comparing the average level of p24 production in drug-free control cell cultures. All assays were performed in triplicate.

Selection of highly DRV-resistant HIV-1 variants in vitro. Drug-resistant HIV-1 variants against DRV were generated as previously described (15, 37). Briefly, in the first passage, MT-4 cells (5 × 10⁶) were exposed to 500 TCID₅₀ of each infectious molecular HIV-1 clone and cultured in the presence of DRV at an initial concentration of an IC₅₀. On the last day of each passage (week 1 to 3), 1.5 ml of the cell-free supernatant was harvested and transferred to a culture of fresh uninfected MT-4 cells in the presence of increased concentrations of the drug for the following round of culture. In this round of culture, three drug concentrations (increased by one-, two-, and threefold compared to the previous concentration) were employed. When the replication of HIV-1 in the culture was confirmed by substantial p24 Gag protein production (greater than 200 ng/ml), the highest drug concentration among the three concentrations was used to continue selection (for the next round of culture). This protocol was repetitively used until the drug concentration reached the targeted concentration. Proviral DNA samples obtained from the lysates of infected cells were subjected to nucleotide sequencing.
Determination of nucleotide sequences. Molecular cloning and determination of the nucleotide sequences of HIV-1 strains passaged in the presence of each compound were performed as previously described (15). In brief, high-molecular-weight DNA was extracted from HIV-1-infected MT-4 cells by using the InstaGene Matrix (Bio-Rad Laboratories, Hercules, CA) and was subjected to molecular cloning, followed by sequence determination. The primers used for the PCR with the entire Gag- and protease-encoding regions of the HIV-1 genome were LTR F2 (5'-GAG ACT CTG GTA ACT AGA GAT C-3') and Ksma2.1 (5'-CCA CCC GCT TTA ATT TTA CTG GTA C-3'). The PCR mixture consisted of 1 μl of proviral DNA solution, 10 μl of Premix Taq (Ex Taq version; TaKaRa Bio Inc., Otsu, Japan), and 10 pmol of each of the PCR primers in a total volume of 20 μl. The PCR conditions used were as follows: (i) an initial step of 1 min at 95°C; (ii) 30 cycles, with 1 cycle consisting of 40 s at 95°C, 20 s at 55°C, and 2 min at 72°C; (iii) a final extension step of 10 min at 72°C. The PCR products were purified with spin columns (MicroSpin S-400 HR columns; Amersham Biosciences Corp., Piscataway, NJ), cloned directly, and subjected to sequencing with a model 3130 automated DNA sequencer (Applied Biosystems, Foster City, CA).

Generation of recombinant HIV-1 clones. The PCR products obtained as described above were digested with two enzymes Apal and Xmal, and the resulting fragments were introduced into pHIV-1NL5sm, designed to have an Xmal site by changing two nucleotides (2590 and 2593) of pHIV-1NL4-3. To generate HIV-1 clones carrying the intended mutation(s), site-directed mutagenesis using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) was used, and the genomic fragments containing the mutation(s) were introduced into pHIV-1NL5sm. Determination of the nucleotide sequences of plasmids confirmed that each clone had the desired mutations but no unintended mutations. Each recombinant plasmid was transfected into COS-7 cells with Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA), and infectious virions thus obtained were harvested 72 h after transfection and stored at –80°C until use.

Competitive HIV-1 replication assay. In order to compare the replicative capability or fitness of two titrated infectious clones, the competitive HIV-1 replication assay (19) was conducted. Briefly, a fixed amount (200 TCID₅₀) of one infectious clone was combined with three different amounts (100, 200, and 300 TCID₅₀) of the other infectious HIV-1 clone and added to the culture of MT-4 cells. On the following day, one-third of the infected MT-4 cells were harvested and washed twice with phosphate-buffered saline (PBS), and cellular DNA was extracted and subjected to PCR and sequencing as described above. The proportions of the mixture were estimated by the heights of the electropherogram obtained from direct sequencing. The HIV-1 cocculture, which best approximated a 50:50 mixture on day 1, was further propagated in the assay. Every 7 days, the cell-free supernatants of virus coculture were transmitted to fresh uninfected MT-4 cells. The cells harvested at the end of each passage (7 days) were subjected to direct DNA sequencing, and viral population changes in terms of percent population of each clone were determined. The persistence of the original amino acid substitutions was confirmed for all infectious clones used in the assay.

Generation of FRET-based HIV-1 expression system. The intermolecular fluorescence resonance energy transfer (FRET)-based HIV-1 expression assay employing protease (PR) monomers tagged with cyan and yellow fluorescent protein (CFP and YFP, respectively) was performed as previously described (4). In brief, CFP- and YFP-tagged HIV-1 protease constructs were generated using BD Creator DNA cloning kits (BD Biosciences, San Jose, CA). For the generation of full-length molecular infectious clones containing CFP- or YFP-tagged protease, the PCR-mediated recombination method was used (38). A linker consisting of five alanines was inserted between protease and fluorescent proteins. The phenylalanine-proline site where HIV-1 protease cleaves was also introduced between the fluorescent protein and reverse transcriptase. DNA fragments obtained were subsequently joined by using the PCR-mediated recombination reaction performed under the standard conditions for Ex Taq polymerase (TaKaRa Bio Inc., Otsu, Japan). The amplified PCR products were cloned into the pCR-XL-TOPO vector according to the manufacturer’s instructions (Gateway Cloning System; Invitrogen, Carlsbad, CA). PCR products containing the HIV-PRWT and HIV-PRWT-coding genes were generated with pCRT-XL-TOPO vector as the templates, followed by digestion with both Apal and Xmal, and the Apal-Xmal fragment was introduced into pHIV-1NL5sm, generating pHIV-PRWT and pHIV-PRWT, respectively.

FRET procedure. COS-7 cells plated on EZ view cover-glass bottom culture plates (Iwaki, Tokyo, Japan) were transfected with pHIV-PRWT and pHIV-PRWT using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions in the presence of various concentrations of DRV, cultured for 72 h, and analyzed under a Leica TCS SP8 confocal microscope (Leica Microsystems, Inc., Wetzlar, Germany) at room temperature as previously described (4). DRV was added to the culture medium simultaneously with plasmid transfection. Results of FRET were determined by quenching of CFP (donor) fluorescence and an increase in YFP (acceptor) fluorescence (sensitized emission), since part of the energy of CFP is transferred to YFP instead of being emitted. The changes in the CFP and YFP fluorescence intensity in the images of selected regions were examined and quantified using Leica Application Suite X software. Background values were obtained from the regions where no cells were present and were subtracted from the values for the cells examined for all calculations. The ratios of intensities of CFP fluorescence after photobleaching to CFP fluorescence before photobleaching (CFP₁₀₀% ratios) were determined. It is well established that CFP₁₀₀% ratios of greater than 1.0 indicate that CFP- and YFP-tagged proteins were associated, and it was interpreted as evidence that protease subunits had dimerized. CFP₁₀₀% ratios of less than 1 indicate that the two subunits were not associated and were interpreted as inhibition of protease dimerization (4).

Structural analysis. We used the coordinates from the X-ray crystal structures of DRV-PRWT complex (PDB ID 4HLA) (20) and APV-PRWT complex (PDB ID 1HPV) (39). Hydrogens were added to the crystal structure, the protonation states of aspartates were assigned, and a restrained minimization was
performed followed by a full minimization. Vol-32 in the structures was "mutated" to Ile, and the structures were again fully minimized using OPLS3 force field, and used for subsequent analysis. Connolly molecular surfaces for the inhibitors and selected protease residues from the active site were generated using a water sphere with a radius of 1.4 Å as a probe. MAESTRO (version 10.7.015, release 2016-3) and associated software tools from Schrödinger, LLC, New York, NY, were used for model building, visualization, and analysis.

ACKNOWLEDGMENTS

This project was supported in part by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, National Institutes of Health, by grants for the Promotion of AIDS Research from the Ministry of Health, Welfare, and Labor of Japan, by grants from the Japan Agency for Medical Research and Development (AMED), by the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), by a grant from the National Center for Global Health and Medicine (NCGM) Research Institute (to H.M.), and by a grant from the National Institutes of Health (GM53386 to A.K.G.). This work was also supported in part by the Platform Project for Supporting Drug Discovery and Life Science Research (Platform for Drug Discovery, Informatics, and Structural Life Science) funded by MEXT and AMED.

This study utilized the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, MD (https://hpc.nih.gov/).

REFERENCES

1. Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, Burchell AN, Cohen M, Gebo KA, Gill MJ, Justice A, Kirk G, Klein MB, Korthuis PT, Martin J, Napravnik S, Rourke SB, Sterling TR, Silverberg MJ, Deeks S, Jacobson LP, Bosch RJ, Kitahata MM, Goedert JJ, Moore R, Gange SJ, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of leDEA. 2013. Closing the gap: increases in life expectancy among treatment eligible HIV-positive individuals in the United States and Canada. PLoS One 8:e881355. https://doi.org/10.1371/journal.pone.0081355.

2. Marcus JL, Chao CR, Leyden WA, Xu L, Quesenberry CP, Jr, Klein DB, Towner WJ, Horberg MA, Silverberg MJ. 2016. Narrowing the gap in life expectancy between HIV-infected and HIV-uninfected individuals with access to care. J Acquir Immune Defic Syndr 73:39–46. https://doi.org/10.1097/QAI.0000000000001014.

3. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. 2017. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV: DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, Office of AIDS Research Advisory Council, US Department of Health and Human Services, Washington, DC.

4. Koh Y, Matsumi S, Das D, Amano M, Davis DA, Li J, Leschenko S, Baldridge A, Shioda T, Yarchoan R, Ghosh AK, Mitsuya H. 2007. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem 282:28709–28720. https://doi.org/10.1074/jbc.M703938200.

5. Koh Y, Aoki M, Danish ML, Aoki-Ogata H, Amano M, Das D, Shafer RW, Ghosh AK, Mitsuya H. 2011. Loss of protease dimerization inhibition activity of darunavir is associated with the acquisition of resistance to darunavir by HIV-1. J Virol 85:10079–10089. https://doi.org/10.1128/JVI.05121-11.

6. Hayashi H, Takamune N, Nirasawa T, Aoki M, Morishita Y, Das D, Koh Y, Ghosh AK, Misumi S, Mitsuya H. 2014. Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir. Proc Natl Acad Sci U S A 111: 12234–12239. https://doi.org/10.1073/pnas.1400027111.

7. De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, Wigerink P, de Béthune MP. 2005. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 49:2314–2321. https://doi.org/10.1128/AAC.49.6.2314-2321.2005.

8. Koh Y, Amano M, Tomowa T, Danish M, Leschenko-Yashchuk S, Das D, Nakayama M, Tojo Y, Ghosh AK, Mitsuya H. 2010. In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple tional protease inhibitors. J Virol 84:11961–11969. https://doi.org/10.1128/JVI.00967-10.

9. Aoki M, Hayashi H, Yedidi RS, Martyr CD, Takamatsu Y, Aoki-Ogata H, Nakamura T, Nakata H, Das D, Yamagata Y, Ghosh AK, Mitsuya H. 2015. C-5-modified tetrahydropyrano-tetrahydofuran-derived protease inhibitors (PIs) exert potent inhibition of replication of HIV-1 variants highly resistant to various PIs, including darunavir. J Virol 90:2180–2194. https://doi.org/10.1128/JVI.01829-15.

10. Aoki M, Hayashi H, Rao KV, Das D, Higashi-Kuwata N, Bulut H, Aoki-Ogata H, Takamatsu Y, Yedidi RS, Davis DA, Hattori S, Nishida N, Hasegawa K, Takamune N, Nyalapatla PR, Osswald HL, Jono H, Saito H, Yarchoan R, Misumi S, Ghosh AK, Mitsuya H. 2017. A novel central nervous system-penetrating protease inhibitor overcomes human immunodeficiency virus 1 resistance with unprecedented aM to pM potency. eLife 6:e28200. https://doi.org/10.7554/eLife.28200.

11. Ide K, Aoki M, Amano M, Koh Y, Yedidi RS, Das D, Leschenko S, Chapsal B, Ghosh AK, Mitsuya H. 2011. Novel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydofuran, that are potent against multi-PI-resistant HIV-1 variants. Antimicrob Agents Chemother 55:1717–1727. https://doi.org/10.1128/AAC.01540-10.

12. Dierynck I, Van Marck H, Van Ginderen M, Jonckers TH, Nalam MN, Schiffer CA, Raof A, Kraus G, Pirchio G. 2011. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors. Antimicrob Agents Chemother 55:5723–5731. https://doi.org/10.1128/AAC.00748-11.

13. Mitsuya Y, Liu TF, Rhee SY, Fessel WJ, Shafer RW. 2007. Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment. J Infect Dis 196:1177–1179. https://doi.org/10.1086/521624.

14. Tang MW, Shafer RW. 2012. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 72:e1–e25. https://doi.org/10.2165/11636360-000000000-00000.

15. Aoki M, Venzon DJ, Koh Y, Aoki-Ogata H, Miyakawa T, Yoshimura K, Maeda K, Mitsuya H. 2009. Non-cleavage site gag mutations in amprnavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprnavir resistance but delay development of resistance to other protease inhibitors. J Virol 83: 3059–3068. https://doi.org/10.1128/JVI.02539-08.

16. Doyon L, Tremblay S, Bourgon L, Wardrop E, Cordingley MG. 2005. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res 68:27–35. https://doi.org/10.1016/j.antiviral.2005.07.003.

17. Svicher V, Ceccherini-Silberstein F, Erba F, Santoro M, Gori C, Bellochi

March/April 2018 Volume 9 Issue 2 e02425-17
MC, Giannella S, Trotta MP, Monforte A, Antoniari A, Perno CF. 2005. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrob Agents Chemother 49:2015–2025. https://doi.org/10.1128/AAC.49.5.2015-2025.2005.

18. Shafer RW. 2006. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 194(Suppl 1):S51–S58. https://doi.org/10.1086/505356.

19. Kosalaraksa P, Kvick MF, Maroun V, Le R, Mitsuya H. 1999. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay. J Virol 73:5356–5363.

20. Yedidi RS, Maeda K, Fyvie WS, Steffey M, Davis DA, Palmer I, Aoki M, Kaufman JD, Stahl SJ, Garimella H, Das D, Wingfield PT, Ghosh AK, Mitsuya H. 2013. P2’ benzene carboxylic acid moiety is associated with decrease in cellular uptake: evaluation of novel nonpeptidic HIV-1 protease inhibitors containing P2 bis-tetrahydrofuranyl moiety. Antimicrob Agents Chemother 57:4920–4927. https://doi.org/10.1128/AAC.00868-13.

21. Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, Pillay D, Shafer RW, Richman DD. 2017. Update of the drug resistance mutations in HIV-1. Top Antivir Med 24:132–133.

22. Garriga C, Pérez-Elias MJ, Delgado R, Ruiz L, Nájera R, Pumarola T, del Mar Alonso-Socas M, García-Bujalance S, Menéndez-Arias L, Spanish Group for the Study of Antiretroviral Drug Resistance. 2007. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med Virol 79:1617–1628. https://doi.org/10.1002/jmv.20986.

23. Dolling Di, Dunn DT, Sutherland KA, Pillay D, Mbisa JL, Parry CM, Post FA, Sabin CA, Cane PA, UK HIV Drug Resistance Database (UKHDDR), UK Collaborative HIV Cohort Study (UK CHIC). 2013. Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother 68:2339–2343. https://doi.org/10.1093/jac/dkt199.

24. Serrantino G, Zaccarelli M, Colao G, Baldanti F, Di Giambenedetto S, Cari T, Maggiori F, Zazz M, ARCA Database Study Group. 2012. Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis. Infection 40:311–318. https://doi.org/10.1007/s15010-011-0237-y.

25. Clemente JC, Hemrajani R, Blum LE, Goodenow MM, Dunn BM. 2003. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N. Biochemistry 42:15029–15035. https://doi.org/10.1021/bi035701y.

26. Chang MW, Torbett BE. 2011. Accessory mutations maintain stability in drug-resistant HIV-1 protease. J Mol Biol 410:756–760. https://doi.org/10.1016/j.jmb.2011.03.038.

27. Lambert-Niclot S, Flandre P, Canestri A, Peytavin G, Blanc C, Agher R, Soulé C, Wirden M, Katalma C, Calvez V, Marcelin AG. 2008. Factors associated with the selection of mutations conferring resistance to protease inhibitors (PI) in PI-experienced patients displaying treatment failure on darunavir. Antimicrob Agents Chemother 52:491–496. https://doi.org/10.1128/AAC.00909-07.

28. Delaugerre C, Pavie J, Palmer P, Ghosn J, Blanche S, Roudiere L, Domínguez S, Mortier E, Molina JM, de Truchis P. 2008. Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen. AIDS 22:1809–1813. https://doi.org/10.1097/QAD.0b013e2881f7daa.

29. Varghese V, Mitsuya Y, Fessel WJ, Liu TF, Melikian GL, Katzenstein DA, Schiffer CA, Holmes SP, Shafer RW. 2013. Prototypical recombinant multi- protease-inhibitor-resistant infectious molecular clones of human immunodeficiency virus type 1. Antimicrob Agents Chemother 57:4290–4299. https://doi.org/10.1128/AAC.00614-13.

30. Poveda E, de Mendoza C, Martin-Carbonero L, Corral A, Briz V, González-Lahoz J, Soriano V. 2007. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J Antimicrob Chemother 60:885–888. https://doi.org/10.1093/jac/dkm276.

31. Skállová T, Dohnalek J, Duskova J, Petrokova H, Soucek M, Konvalinka J, Hasek J. 2006. HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site. J Med Chem 49:5777–5784. https://doi.org/10.1021/jm0605583.

32. Henderson GJ, Lee SK, Irbeek DM, Harris J, Kline M, Polloom E, Parkin N, Swanstrom R. 2012. Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity. Antimicrob Agents Chemother 56:623–633. https://doi.org/10.1128/AAC.05549-11.

33. Günthard HF, Aberg JA, Eron JJ, Hoy JF, Templin A, Benson CA, Burger DM, Cahn P, Gallant JE, Clesby MJ, Reiss P, Saag MS, Thomas DL, Jacobsen DM, Volberding PA, International Antiviral Society–USA Panel. 2014. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society–USA Panel. JAMA 312:410–425. https://doi.org/10.1001/jama.2014.8722.

34. de Meyer S, Vangeneugden T, van Baelen B, de Paep E, van Marck H, Picchio G, Lefebvre E, de Béthune MP. 2008. Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 24:379–388. https://doi.org/10.1089/aid.2007.0173.

35. Ghosh AK, Leschchenko S, Noetzle M. 2004. Stereoselective photochemical 1,3-dioxolan addition to 5-alkoxyphenyl-2(3H)-furanone: synthesis of bis-tetrahydrofuranyl ligand for HIV protease inhibitor UIC-94017 (TMC-114). J Org Chem 69:7822–7829. https://doi.org/10.1021/jo049156y.

36. Yoshimura K, Kato R, Yusa K, Kvick MF, Maroun V, Nguyen A, Mimoto T, Ueno T, Shintani M, Falloon J, Masur H, Hayashi H, Erickson J, Mitsuya H. 1999. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci U S A 96:8675–8680. https://doi.org/10.1073/pnas.96.15.8675.

37. Aoki M, Danish ML, Aoki-Ogata H, Amano M, Ide K, Das D, Koh Y, Mitsuya H. 2012. Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1. J Virol 86:13384–13396. https://doi.org/10.1128/JVI.07234-11.

38. Fang G, Weiser B, Visosky A, Moran T, Burger H. 1999. PCRameditated recombination: a general method applied to construct chimeric infectious molecular clones of plasma-derived HIV-1 RNA. Nat Med 5:239–242. https://doi.org/10.1038/5607.

39. Kim EE, Baker CT, Dwyer MD, Murcko MA, Burger MA, Rao BG, Tung RD, Navia MA. 1993. Crystal structure of HIV-1 protease in complex with VX-478, a potent and orally bioavailable inhibitor of the enzyme. J Am Chem Soc 115:1181–1182. https://doi.org/10.1021/ja00108a056.